Jeff Jones
Stock Analyst at Oppenheimer
(3.84)
# 668
Out of 5,150 analysts
99
Total ratings
29.21%
Success rate
19.27%
Average return
Main Sectors:
Stocks Rated by Jeff Jones
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PTHS Pelthos Therapeutics | Maintains: Outperform | $57 → $60 | $24.19 | +148.04% | 3 | Jan 26, 2026 | |
| CRVS Corvus Pharmaceuticals | Maintains: Outperform | $15 → $32 | $17.53 | +82.54% | 6 | Jan 21, 2026 | |
| VTYX Ventyx Biosciences | Downgrades: Perform | n/a | $14.00 | - | 12 | Jan 8, 2026 | |
| KYMR Kymera Therapeutics | Maintains: Outperform | $67 → $120 | $86.35 | +38.97% | 7 | Dec 9, 2025 | |
| CMMB Chemomab Therapeutics | Maintains: Outperform | $10 → $25 | $1.79 | +1,294.31% | 9 | Aug 27, 2025 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Outperform | $56 → $53 | $8.21 | +545.55% | 10 | Aug 6, 2025 | |
| AVBP ArriVent BioPharma | Maintains: Outperform | $39 → $44 | $23.94 | +83.79% | 3 | Jun 24, 2025 | |
| ALMS Alumis | Maintains: Outperform | $26 → $25 | $28.15 | -11.19% | 3 | May 15, 2025 | |
| ZURA Zura Bio | Maintains: Outperform | $19 → $17 | $6.49 | +161.94% | 4 | May 9, 2025 | |
| IMCR Immunocore Holdings | Maintains: Outperform | $85 → $86 | $32.36 | +165.76% | 2 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $18 | $3.51 | +412.82% | 4 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $2.68 | - | 5 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $22 → $16 | $5.17 | +209.48% | 7 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $45 | $1.25 | +3,500.00% | 6 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $8.80 | - | 4 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $1.06 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $2.64 | - | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $15 | $1.62 | +825.93% | 5 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $1,875 | $2.27 | +82,499.12% | 2 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $1,600 → $1,100 | $3.12 | +35,156.41% | 2 | Nov 17, 2022 |
Pelthos Therapeutics
Jan 26, 2026
Maintains: Outperform
Price Target: $57 → $60
Current: $24.19
Upside: +148.04%
Corvus Pharmaceuticals
Jan 21, 2026
Maintains: Outperform
Price Target: $15 → $32
Current: $17.53
Upside: +82.54%
Ventyx Biosciences
Jan 8, 2026
Downgrades: Perform
Price Target: n/a
Current: $14.00
Upside: -
Kymera Therapeutics
Dec 9, 2025
Maintains: Outperform
Price Target: $67 → $120
Current: $86.35
Upside: +38.97%
Chemomab Therapeutics
Aug 27, 2025
Maintains: Outperform
Price Target: $10 → $25
Current: $1.79
Upside: +1,294.31%
Corbus Pharmaceuticals Holdings
Aug 6, 2025
Maintains: Outperform
Price Target: $56 → $53
Current: $8.21
Upside: +545.55%
ArriVent BioPharma
Jun 24, 2025
Maintains: Outperform
Price Target: $39 → $44
Current: $23.94
Upside: +83.79%
Alumis
May 15, 2025
Maintains: Outperform
Price Target: $26 → $25
Current: $28.15
Upside: -11.19%
Zura Bio
May 9, 2025
Maintains: Outperform
Price Target: $19 → $17
Current: $6.49
Upside: +161.94%
Immunocore Holdings
May 8, 2025
Maintains: Outperform
Price Target: $85 → $86
Current: $32.36
Upside: +165.76%
Jan 24, 2025
Maintains: Outperform
Price Target: $28 → $18
Current: $3.51
Upside: +412.82%
Dec 11, 2024
Downgrades: Perform
Price Target: n/a
Current: $2.68
Upside: -
Nov 22, 2024
Maintains: Outperform
Price Target: $22 → $16
Current: $5.17
Upside: +209.48%
Aug 8, 2024
Maintains: Outperform
Price Target: $48 → $45
Current: $1.25
Upside: +3,500.00%
Jun 7, 2024
Downgrades: Perform
Price Target: n/a
Current: $8.80
Upside: -
Apr 1, 2024
Reiterates: Perform
Price Target: n/a
Current: $1.06
Upside: -
May 23, 2023
Downgrades: Perform
Price Target: n/a
Current: $2.64
Upside: -
May 11, 2023
Reiterates: Outperform
Price Target: $15
Current: $1.62
Upside: +825.93%
Mar 24, 2023
Reiterates: Outperform
Price Target: $1,875
Current: $2.27
Upside: +82,499.12%
Nov 17, 2022
Maintains: Outperform
Price Target: $1,600 → $1,100
Current: $3.12
Upside: +35,156.41%